POR Campania FESR 2014-2020
SoftMining has developed an innovative AI-based platform to reduce the cost and time associated with the design of new molecules. The MIND (Molecules Inhibiting Neurodegenerative Diseases) project involves the application of the AI-based platform for the design, synthesis and preclinical characterization of molecules for neurodegenerative diseases.
The project was co-funded by the European Union, the Italian State and the Campania Region under the POR Campania FESR 2014-2020.
The funding allowed to identify a potential drug candidate, and to begin patent deposition activities for “Bioactive compounds and methods for treatment of neurodegenerative disease”.
EU4 Health Programme
The aim of the NEWROAD project is to develop an EU-wide capability for Systematic Drug Repurposing (SDR). To achieve this NEWROAD will develop an open, collaborative in silico platform for the repurposing of drugs in oncology based on Augmented Intelligence (AuI) architecture layered on top of Artificial Intelligence (AI) algorithms, initially targeted at rare and paediatric cancer research.
The platform will be designed with easy-to-use yet powerful AI features that aim to encourage researcher engagement and collaboration. NEWROAD will be deployable on a network of high-performance computers and in the cloud, and will leverage data provided by hospitals, clinics, pharmaceutical companies etc. in the European Community.
This project is co-funded by the European Union EU4 Health Programme (EU4H) under grant agreement No 101080024 – NEWROAD.
SoftMining has developed an innovative AI-powered platform for the design and identification of new molecules to use in therapy. The MIND (Molecules Inhibiting Neurodegenerative Diseases) project involves the application of the AI-powered platform for the design, synthesis and preclinical characterization of molecules for neurodegenerative diseases.
This project is co-funded by the Ministry of University and Research as part of the Eureka EUROSTARS Programme.
The funding will allow to complete and expand the AI-powered platform an to identify new potential drug candidates for the treatment of neurodegenerative diseases.